1. Natural product drug discovery {#sec0005}
=================================

The need for novel chemical compounds to treat human diseases is ever increasing. The rapid development of drug-resistant microbes, the discovery of new cases of life-threatening infections, and the constant recurrence of diseases have pushed for advances in the field of drug discovery ([@bib0775], [@bib0225]). In principle, there are three pathways for discovering new pharmacologically significant compounds: rational drug design, where the drug is purposefully tailored towards specific targets in the microbial cell ([@bib0470]); combinatorial chemistry, which involves synthesis of a combinatorial library of compounds, which are then tested against the cellular target to determine the most potent compounds ([@bib0290]); and natural product discovery, by isolating bioactive compounds from biological sources ([@bib0780]). Of late, pharmaceutical companies have shifted their interest towards the first two pathways. These pathways utilise the latest advances in three-dimensional X-ray crystallography, drug-docking tools, and other computer-aided methodologies ([@bib0535]) which significantly cut the development time of a compound, from compound synthesis to market delivery. There are, however, downfalls with these approaches, including the high cost to discover novel compounds and for production. Moreover, until the detailed mechanisms of targeted cellular death and survival are comprehensively elucidated, it will remain difficult to select potential targets for structure-guided drug design ([@bib0075]). Furthermore, being laboratory-synthesised compounds, combinatorial compounds are often insufficiently complex, possessing limited structural rigidity, and require extensive purification steps and bioactivity testing to conclusively characterise the bioactive compounds ([@bib0060]). In addition, there has been a steady increase in the negative public perception regarding the use of synthetic drugs due to their long-term safety and environmental concerns ([@bib0770]). Consequently, efforts are being made to re-explore the potential of natural products as sources of novel drugs ([Fig. 1](#fig0005){ref-type="fig"} ).Fig. 1Graphical representation of natural product drug discovery approach discussed in this review.

2. The ethnobotanical approach to drug discovery {#sec0010}
================================================

Natural products, generally secondary metabolites, are produced by an organism in response to external stimuli such as nutritional changes or foreign infection ([@bib0780]). They constitute almost 50% of the new drugs introduced to the market from 1981 to 2010, and approximately 75% of anti-infective agents are natural products or natural-product derivatives ([@bib0550]). Most bioactive natural products have the ability to target specific proteins coded by essential genes ([@bib0410]). While it is understood that this property cannot be fully utilised for human genetically linked diseases due to the more complex human protein-protein interactions ([@bib0200]), this attribute has been widely explored for the treatment of infectious diseases, as these compounds are able to specifically target the infective agents ([@bib0410]). For example, beta-lactam antibiotics, such as the penicillins and the cephalosporins, are largely used for their broad antibacterial spectrum and outstanding safety profile for human use ([@bib0205]).

Of all possible sources of natural products, plants have been viewed as one of the most promising. The plant kingdom provides a plethora of biologically active compounds, and it is estimated that only 10--15% of existing species of higher plants have been investigated ([@bib0100]). Of this, only approximately 6% have been screened for biological activity ([@bib0825]). Medicinal plant use can be traced to ancient agricultural societies, where indigenous populations have utilised them as therapies for many diseases ([@bib0210]). Even in the modern era, approximately 80% of the world\'s population, particularly those in the developing countries, still rely on herbal medicines for their primary healthcare ([@bib0340]). Historically, plants with healing properties have been discovered and utilised even before the cause of the disease has been fully identified. Not surprisingly, the trial and error approach has been utilised for generations in these cultures to discover plants of medicinal value.

Unfortunately, while most traditional cultures have utilised plants for medicinal purposes, this precious knowledge has generally been kept secret by traditional healers or the information is kept within their own community. The information transfer between these traditional healers and modern society is largely the result of the work by ethnobotanists, who study plant-human inter-relationships in natural and social contexts ([@bib0020]). Since its inception, the field of ethnobotany has evolved from merely a collection of information regarding plants utilised by a particular community into a more complex, interdisciplinary research area of understanding the biological and socio-economic impacts of using the plants to the development of a particular culture.

Ethnobotanical knowledge has provided sufficient basis for further investigation of traditional plants for their medicinal properties. Modern scientists have revisited these traditional uses of the plants and carried out bioprospecting, which involves screening for natural products with biological activity ([@bib0770], [@bib0045]), in order to isolate and identify the chemical entities responsible for treating diseases. Since the discovery of penicillin in 1928 ([@bib0280]) and its mass production during World War II, modern medicine has utilised natural products as single, pharmaceutical entities and concerted efforts have been made to isolate and identify these individual bioactive compounds.

In the recent past, isolating biologically active natural products was not a preferred pathway of drug discovery as it was time consuming and resource inefficient. Nonetheless, the rate of bioassay-guided fractionation has recently been significantly improved with advances in instrumentation, such as high-performance liquid chromatography (HPLC), mass spectrometry (MS), higher magnetic field-strength nuclear magnetic resonance (NMR) instruments, and robotic technology ([@bib0675]). Compounds of limited availability in their organisms of origin are now detectable with the introduction of capillary NMR spectroscopy ([@bib0490]), while the development of automated high-throughput screening techniques have replaced bioassays as a rate-limiting step of drug discovery ([@bib0835]). These advances have made the list of natural products with therapeutic value ever increasing and an abundance of new compounds are continually being isolated.

Ethnobotanical knowledge has led to the isolation of novel bioactive compounds. However, plant availability is viewed to be the limiting factor in the commercial success of some natural products. At times, a large quantity of plant is required to produce sufficient amounts of the bioactive compounds for clinical use. In other cases, compounds have been isolated from endangered or highly endemic plants. This raises major concerns regarding biodiversity conservation. Plant tissue culture offers a solution ([@bib0505]), although the cost of such production methods is high. One of the advances in addressing these issues is the discovery that microorganisms residing inside the plant tissues may produce similar, if not the same, bioactive compounds as their plant hosts. From a commercial point of view, it is relatively easier to scale up the fermentation process of microbes, enabling large-scale production of biologically active compounds to meet industrial demands. These microorganisms present the opportunity to discover a plethora of compounds and offer a renewable source of natural products.

3. Endophytes as sources of natural products {#sec0015}
============================================

Endophytes refer to the microorganisms (mostly fungi and bacteria) colonising the intercellular and intracellular regions of healthy plant tissues at a particular time, whose presence is unobtrusive and asymptomatic ([@bib0695], [@bib0755], [@bib0765]). Most plant species that have been previously studied host at least one endophytic microbe ([@bib0665]), with plants growing in unique environmental settings generally hosting novel endophytic microorganisms ([@bib0765]).

Endophytes form a symbiotic relationship with their plant host. It is believed that in many cases the microbes function as the biological defence for the plant against foreign phytopathogens. The protection mechanism of the endophytes are exerted directly, by releasing metabolites to attack any antagonists or lyse affected cells, and indirectly, by either inducing host defence mechanisms or promoting growth.

Antibiotics or hydrolytic enzymes can be released by endophytes to prevent colonisation of microbial plant pathogens ([@bib0765], [@bib0085]), or prevent insects ([@bib0055]) and nematodes ([@bib0345]) from infecting plants. In other cases endophytes release metabolites which activate host defence mechanism against other pathogenic organisms, in a process known as induced systemic resistance ([@bib0415]). Similarly, endophytes can also promote plant growth in an attempt to outcompete cell apoptosis induced by infecting pathogens ([@bib0085]). Plant growth promotion by endophytes may be exerted by several mechanisms, such as production of phytohormones ([@bib0820]), synthesis of siderophores ([@bib0560]), nitrogen fixation, solubilisation of minerals such as phosphorus ([@bib0640]), or *via* enzymatic activities, such as ethylene suppression by 1-aminocyclopropane-1-carboxylate deaminase ([@bib0310]). The plant host also benefits from the endophytes by their natural resistance to soil contaminants ([@bib0720]), their ability to degrade xenobiotics, or their action as vectors to introduce degradative traits to plants, which substantially assist phytoremediation ([@bib0665]).

Endophytes can produce the same or similar secondary metabolites as their host. Bioactive compounds which are co-produced by the plants as well as their associated endophytes include the anticancer drug camptothecin ([@bib0600]), the anticancer drug lead compound podophyllotoxin ([@bib0605]), and the natural insecticide azadirachtin ([@bib0440]). There are several mechanisms proposed for the simultaneous production of these biological compounds. In some cases, such as that of gibberellin, the biosynthetic mechanism of the same compound evolves independently in plants and their microbial counterparts ([@bib0105]). On the other hand, horizontal gene transfer between the plant host and its endophytes have long been hypothesised, although so far this process has only been shown to occur between microbial endophytes ([@bib0785]). It has been strongly suggested, however, that interactions between endophytes and their respective plant host contributes to the co-production of these bioactive molecules ([@bib0370]).

Endophytes have recently generated significant interest in the microbial chemistry community due to their immense potential to contribute to the discovery of new bioactive compounds. It has been suggested that the close biological association between endophytes and their plant host results in the production of a greater number and diversity of biological molecules compared to epiphytes or soil-related microbes ([@bib0765]). Moreover, the symbiotic nature of this relationship indicates that endophytic bioactive compounds are likely to possess reduced cell toxicity, as these chemicals do not kill the eukaryotic host system. This is of significance to the medical community as potential drugs may not adversely affect human cells.

One of the most successful stories of natural products from endophytes is the multibillion-dollar anticancer drug Taxol (paclitaxel). The compound was initially isolated from the Pacific yew tree, *Taxus brevifolia* ([@bib0840]), a traditional medicinal plant used by Native Americans ([@bib0335]). Since then, several other plants from the genus *Taxus* have been reported to produce Taxol. Nonetheless, these plants are slow-growing with generally isolated geographical distribution. Investigations of endophytes from this plant revealed that some fungi, such as *Taxomyces andreanae*, also produced the exact same compound ([@bib0750]). The biological production of this compound in *Taxus* plants have been characterised ([Fig. 2](#fig0010){ref-type="fig"} ). While horizontal gene transfer has long been proposed for the biosynthesis of Taxol in endophytes, it has been recently showed that the endophyte genomes did not contain any sequences with significant homology to the Taxol biosynthetic genes from *Taxus* spp. ([@bib0370]), indicating Taxol biosynthesis in endophytes might have developed independently from its plant host. Nevertheless, this example supports the rationale that traditional medicinal plants can be used as the starting point to investigate endophytes for their production of biologically active compounds.Fig. 2Graphical representation of taxol biosynthesis in *Taxus* spp. (adapted from [@bib0830]). Multiple arrows indicate several as yet undefined steps.

As mentioned earlier, approximately three quarters of anti-infectives are natural products or natural-product derived structures. However, rather than using combinatorial chemistry to synthesise these derivatives, the biosynthesis of these natural products has been elucidated at the genetic level. As the synthesis of most of these natural products is regulated by single gene clusters, numerous research groups have attempted to isolate these clusters and utilise genetic engineering to biologically synthesise the native compounds as well as their derivatives. Two of the most studied and largest classes of secondary metabolites are the polyketides and non-ribosomal peptides ([@bib0380]).

4. Biosynthesis of natural product secondary metabolites {#sec0020}
========================================================

Peptide antibiotics constitute some of the most important anti-infective drugs on the market, most notably the β-lactams such as the penicillins and the cephalosporins ([@bib0565]). These oligopeptides are synthesised by large, multimodular enzyme complexes called non-ribosomal peptide synthetases (NRPSs), which use proteinogenic and non-proteinogenic amino acids as their building blocks. NRPSs consist of a series of modules, each consisting of catalytic units essential for amino acid recognition (adenylation domain), activation (peptidyl carrier protein), and bond formation of the growing peptide chain (condensation domain) ([@bib0275]).

Variable arrangements of modules and the possible inclusion of numerous tailoring reactions have resulted in a vast array of non-ribosomal peptide scaffolds in nature. High versatility of the modules and domains in terms of both catalytic potential and interaction within the multifunctional protein templates has led to the classification of NRPS systems: linear (type A), iterative (type B), and nonlinear (type C) ([@bib0525]). In linear (type A) NRPSs, the multiple modules are arranged in a sequential fashion, where each module incorporates one monomer in to the growing chain during each production cycle. In contrast, in iterative (type B) NPRS systems, the modules or domains are used multiple times in the assembly of a single product, thus creating a multimeric peptide consisting of repeated smaller sequences. The third type, non-linear (type C) NRPSs are the most sophisticated system, consisting of domains and modules organised in a non-conventional manner. The deviation from the traditional C-A-PCP arrangement is often followed by unusual internal cyclisation or branch-point syntheses, resulting in non-linear peptide products.

An example of a type A NRPS product is daptomycin, a cyclic lipopeptide which represented the first new class of antibiotics introduced in 30 years when it was approved by the Food and Drug Administration (FDA) in 2003 ([@bib0610]). Naturally produced by the actinomycete *Streptomyces roseosporus* NRRL11379, daptomycin consists of a cyclic core of 13 amino-acids, six of which are non-proteinogenic, and an N-terminal decanoyl lipid ([Fig. 3](#fig0015){ref-type="fig"}A) ([@bib0515]). Valinomycin, a potent antibiotic against severe acute respiratory syndrome coronavirus, provides a good model of the type B (iterative) NRPS system. Produced by several *Streptomyces* isolates, the biosynthetic gene cluster has been isolated from *Streptomyces tsusimaensis* ATCC15141 ([Fig. 3](#fig0015){ref-type="fig"}B) ([@bib0145]). The third type, non-linear (type C) NRPSs, is responsible for biosynthesis of the potent anti-tuberculosis compound capreomycin. Isolated from *Saccharothrix mutabilis* subsp. *capreolus*, analysis of the capreomycin biosynthetic gene cluster revealed that the compound was not assembled by a typical linear or iterative NRPS mechanisms ([Fig. 3](#fig0015){ref-type="fig"}C) ([@bib0265]).Fig. 3Graphical representation of biosynthesis of natural bioactive compounds showing non-ribosomal peptide synthetase (NRPS). (A) Biological production of daptomycin using type A NRPS (adapted from [@bib0515]). (B) Biological production of valinomycin using type B NRPS (adapted from [@bib0145]). (C) Biological production of capreomycin using type C NRPS (adapted from [@bib0265]). Individual NRPS domains are noted as circles with the appropriate abbreviation to indicate their function: Ad = adenylating enzyme, PCP = peptidyl carrier protein, C = condensation domain, A = adenylation domain, E = epimerisation domain, TE = thioesterase domain, TA = transaminase domain, DH~2~ = dehydrogenation domain, X = domain with no known function, C\* = modified condensation domain. The genes or protein responsible for a particular process are noted as boxes.

Similar to the small peptides, polyketides also constitute a large proportion of industrial antibiotics. Among the most prominent examples are the polyene macrolide antibiotics, such as amphotericin B and nystatin ([@bib0295]), as well as the tetracyclines ([@bib0565]). Polyketides are natural products synthesised by polyketide synthases (PKS) which are also large multimodular enzyme complexes that function similarly to a fatty acid synthase (FAS) ([@bib0275]). Resembling the NRPS system, there are three core domains in a typical PKS system: acyltransferase (AT), which acts as the gatekeeper for substrate specificity, selecting and activating the monomers and the intermediate acyl chain; acyl carrier proteins (ACPs), whose phosphopantetheine arm covalently attaches the growing intermediate acyl chain; and ketosynthase (KS) which catalyses C---C bond formation *via* Claisen condensation in the elongation of the polyketide chain ([@bib0275]). Termination is achieved by the action of the thioesterase (TE) domain.

There are several types of PKS systems. Type I PKSs are multifunctional enzymes linearly arranged into modules, each of which consists of a set of non-iteratively acting domains responsible for the catalysis of one cycle of chain elongation ([@bib0095]). Erythromycin, a broad spectrum macrolide antibiotic, is one of the most well-studied compounds of this type ([@bib0625]). First discovered from *Saccharopolyspora erythraea*, the compound consists of a 14-membered macrolactone ring and two glucose derived deoxysugar moieties desosamine and cladinose (3-O-methylmycarose). The construction of its precursor, 6-deoxyerythronolide B (6-deB) is controlled by a large modular protein known as 6-deB synthase (DEBS) ([Fig. 4](#fig0020){ref-type="fig"}A). Type II PKSs consist of several monofunctional enzymes acting iteratively, resulting in the production of polyphenols or other aromatic polyketides ([@bib0375]). An example of this type is the anti-tumour antibiotic doxorubicin, which is produced by the actinomycete *Streptomyces peucetius* ATCC29050 ([Fig. 4](#fig0020){ref-type="fig"}B) ([@bib0320]). Type III PKSs, also known as chalcone synthase-like PKSs, are homodimeric enzymes consisting of multiple ACP-independent modules which essentially are iterative condensing enzymes. Biosynthesis of 2,4-diacetylphloroglucinol, an antibiotic against plant pathogens, from endophytic *Pseudomonas fluorescens* Q2-87 is known to involve a type III polyketide synthase ([Fig. 3](#fig0015){ref-type="fig"}C) ([@bib0300]).Fig. 4Graphical representation of biosynthesis of natural bioactive compounds showing polyketide synthase (PKS). (A) Biological production of erythromycin, highlighting Type I PKS in the formation of 6-deoxyeryhtronolide B, its precursor (adapted from [@bib0125]). (B) Biological production of doxorubicin using Type II PKS (adapted from [@bib0135]). (C) Biological production of 2,4-diacetylphloroglucinol using Type III PKS (adapted from [@bib0325]). The individual PKS domains are noted as curved rectangle with the appropriate abbreviation to indicate their function: AT = acyltransferase domain, ACP = acyl carrier protein, KS = ketosynthase domain, KR = ketoreductase domain, DH = dehydratase domain, ER = enoylreductase domain, KS~α~ = ketosynthase domain which catalyses decarboxylative Claisen condensation of the precursors, KS~β~ = ketosynthase domain which controls the polyketide length. The genes or protein responsible for a particular process are noted as boxes.

Plant-associated microorganisms have been found to produce novel bioactive metabolites with wide-ranging medicinal applications such as antibiotics, immunosuppressants, antiparasitics, and anticancer agents ([@bib0750]). Therefore, it is hypothesised that endophytes could be useful sources of lead compounds in drug discovery. As highlighted earlier, natural products have the ability to target microbial pathogens and this is of interest to the scientific and medical communities since infectious diseases are the leading cause of human mortalities globally. One such disease which is increasingly affecting large human populations is tuberculosis. A number of natural antimycobacterials, discussed later in this review, have also been identified as PKS and NRPS products, especially those produced by bacteria or fungi.

5. Tuberculosis {#sec0025}
===============

Tuberculosis (TB) is a potentially deadly infectious disease caused by *Mycobacterium* sp., mainly *Mycobacterium tuberculosis*. Often infecting the lungs, it can also attack the central nervous system, the lymphatic system, as well as skeletal tissue. Common symptoms of TB include chronic cough with blood-tinged sputum, fever, night sweats, and weight loss. TB is transmitted through the air when infected individuals cough, sneeze, or spit, spreading the bacteria from their throat or lungs.

One--third of the world\'s current population have been infected with *M. tuberculosis* ([@bib0425]). There were approximately 8.8 million reported cases of active TB in 2010, 5.7 million of which are new or relapsed cases. The disease caused approximately 1.5 million deaths ([@bib0860]). Though TB incidence is more common in developing and under-developed countries ([@bib0860]), the rising frequency of population migration has resulted in increased occurrences in developed countries.

6. Current anti-tuberculosis therapies {#sec0030}
======================================

In most cases, TB is curable, provided that the drug regime is followed diligently ([@bib0285]). An anti-TB drug regime is considered successful if all mycobacteria are killed, preventing patient relapse after cessation of treatment, and avoiding the development of drug resistant mycobacteria. As there are naturally occurring drug-resistant mycobacteria at any stage of the infection, it is currently impossible to treat the disease with a single drug ([@bib0330]).

Drugs that are commonly used to treat TB are listed in [Table 1](#tbl0005){ref-type="table"} . A typical drug regime comprises a combination of bactericidal and bacteriostatic drugs. Since the 1950s, the standard first-line therapy for tuberculosis involves a two month treatment with a combination of rifampicin, isoniazid, ethambutol, and pyrazinamide, followed by treatment with a combination of rifampicin and isoniazid for an additional four months ([@bib0330]). Unfortunately, stringent drug therapy is not accessible to most sufferers, particularly those in high burden countries in Asia and Africa. Incomplete treatment of the disease causes the development of drug-resistant TB.Table 1Mechanism of action and causes of resistance development of various anti-tuberculosis chemotherapeutic agent.Chemotherapeutic agentMechanism of actionResistance developmentAminoglycosides: amikacin, kanamycin, streptomycinInhibition of protein synthesis, particularly in translational initiation ([@bib0575])Acquisition of aminoglycoside-inactivating enzymes ([@bib0710]), mutational alteration of target structural gene *rrs* ([@bib0015]) or ribosomal protein ([@bib0270])[d]{.smallcaps}-cycloserine (cyclic analogue of [d]{.smallcaps}-alanine)Inhibition of cell wall biosynthesis ([@bib0350])Overexpression of target gene *alrA* ([@bib0120])EthambutolInhibition of cell wall biosynthesis ([@bib0855], [@bib0445])Mutation in the target operon *embCAB*, particularly the gene *embB* ([@bib0615])Ethionamide and prothionamide (structural analogue of isoniazid)Inhibition of cell wall, particularly mycolic acid, biosynthesis ([@bib0065], [@bib0080])Mutation in the target gene *inhA* ([@bib0065]); overexpression of EthR, a repressor of ethionamide activator ([@bib0255])Fluoroquinolones: ciprofloxacin, gatifloxacin, levofloxacin, moxifloxacin, ofloxacin, sparfloxacinInhibition of DNA replication ([@bib0245])Mutation in target genes *gyrA* ([@bib0245], [@bib0010]) and *gryB* ([@bib0050])IsoniazidInhibition of fatty acid biosynthesis ([@bib0065], [@bib0795], [@bib0655])Mutation in *katG* gene to prevent drug activation ([@bib0890]) and mutation in the target structural gene *inhA* ([@bib0650], [@bib0090])IsoxylInhibition of mycolic acids, oleic acid, tuberculostrearic acid, and other short-chain fatty acids biosynthesis ([@bib0580])Mutation in the target gene *etaA*, and possible cross-resistance between thiocarbonyl-containing antibiotics ([@bib0220])Macrolides: erythromycin, clarithromycin, roxithromycinInhibition of protein synthesis, particularly in translational initiation ([@bib0805])Point mutations in the target 23S rRNA gene ([@bib0510], [@bib0545]); increased expression of *ermMT* gene resulting in substantial loss of drug binding ([@bib0030])Oxazolidinones: linezolid, eperezolid, DA-7157, DA-7218, DA-7867Inhibition of protein synthesis, particularly in translational initiation ([@bib0715])Alteration in the efflux pump or drug transport mechanism ([@bib0645])*p*-Aminosalicylic acidInhibition of folate ([@bib0635]) and thymine nucleotides ([@bib0495]) biosynthetic pathwaysMutations in the target gene *thyA*, though the major cause is yet to be identified ([@bib0495])Phenothiazines: thioridazine, chlorpromazine, trifluoperazineInhibition of cell wall biosynthesis, lipid metabolism ([@bib0630]), and oxidative phosphorylation ([@bib0880])Yet to be identified ([@bib0025])Pyrazinamide (synthetic analogue of nicotinamide)Mechanism not fully understood, though it is thought to be inhibiting vital enzyme activities and disrupting membrane transport ([@bib0365], [@bib0895], [@bib0885])Mutation in the gene *pncA*, preventing drug activation ([@bib0705])Rifamycins: rifampin, rifabutin, rifalazil, rifapentineInhibition of protein synthesis, particularly in transcriptional initiation ([@bib0435]) and induction of programmed cell death ([@bib0250])Mutation in the target structural gene *rpoB* ([@bib0810])Riminophenazines: clofazimine, B746, B4157Disruption to potassium transport ([@bib0155]) and electron transport involved in cellular respiration ([@bib0110])Yet to be identified ([@bib0870])ThiacetazoneDisruption of cell envelope permeability and host immunomodulation ([@bib0005])Mutation in the gene *ethA* ([@bib0220]); possible cross-resistance between thiocarbonyl-containing antibiotics ([@bib0220])Tuberactinomycin: enviomycin/tuberactinomycin N, viomycin, capreomycinInhibition of protein synthesis, particularly in post-transcriptional modification and translational initiation ([@bib0815], [@bib0460], [@bib0845])Single and double mutations in target ribosomal subunit genes ([@bib0265], [@bib0875], [@bib0800])

*M. tuberculosis* has intrinsic drug resistance mechanisms that render most antimicrobials ineffective. Its unique lipid-rich cell envelope structure has low permeability to most clinical antibiotics ([@bib0395]), and it is equipped with drug efflux pumps ([@bib0465]). Provided that the drug is able to penetrate the cell wall, mycobacteria have another complementary system that coordinates resistance to antibiotics inhibiting cytoplasmic targets. On the other hand, *M. tuberculosis* is known to possess genomic plasticity ([@bib0240]). Most cases of drug resistance in *M. tuberculosis* develop *via* mutations of the target genes, such as *rpoB* against rifampicin, *rrs* against kanamycin, and *gyrA* against the fluoroquinones. Multidrug resistance occurs *via* the accumulation of independent mutations in more than one of these genes ([@bib0620]).

One of the major issues in antimycobacterial research is the absence of new drugs with novel mechanisms of action, while resistance has been observed with all current therapeutics. Cutting-edge technologies and more advanced screening processes have resulted in several drug candidates with novel activities currently being tested in later stage clinical trials ([Table 2](#tbl0010){ref-type="table"} ). From these new drug candidates, the semi-synthetic TMC207 has received FDA approval, specifically for patients with MDR-TB, through its accelerated approval programme which based its decision on Phase II trials ([@bib0160], [@bib0230], [@bib0235]). Commercialised under the name bedaquiline, it is the first anti-TB therapy with a novel mechanism of action in more than 40 years ([@bib0555]).Table 2Anti-tuberculosis drug candidates in clinical trials.DrugSponsorClass*In vitro* potencyMode of actionClinical trial statusTMC 207 (Bedaquiline)JanssenDiarylquinoline30--120 ng/ml ([@bib0035], [@bib0420])Targeting ATP synthase, inhibition of proton pumping activity ([@bib0385])III, FDA-approved (accelerated programme) ([@bib0160])PA-824TB AllianceNitroimidazole150--300 ng/ml ([@bib0760])Prevention of cell wall mycolic acid biosynthesis ([@bib0730], [@bib0485], [@bib0475], [@bib0480])II ([@bib0400])OPC 87863 (Delamanid)OtsukaNitroimidazole6--24 ng/ml ([@bib0500])Prevention of cell wall mycolic acid biosynthesis ([@bib0305])III ([@bib0400])SQ109SequellaEthylenediamine200--780 ng/ml ([@bib0670])Inhibition of mycolic acid transport to the cell wall ([@bib0110], [@bib0790])II ([@bib0670])PNU-100480 (Sutezolid)PfizerOxazolidinone120 ng/ml ([@bib0070])Targeting 23S rRNA, inhibition of bacterial protein synthesis ([@bib0570])II ([@bib0400])AZD5847AstraZenecaOxazolidinone-Undisclosed data\--Undisclosed data-II ([@bib0400])

7. The search for new anti-tuberculosis natural products {#sec0035}
========================================================

Natural products have played crucial roles in the treatment of TB. The global effort to decrease the incidence of TB, combined with the rapid development of resistant strains, has increased interest in natural products as sources of novel anti-tubercular compounds. Development of *in vitro* whole organism reporter bioassays ([@bib0140]), purified target (biochemical) bioassays ([@bib0685], [@bib0690]), and *in vivo* bioassays ([@bib0450]) have accelerated the assessment process for drug candidates, and thus considerably increased the discovery rate of new compounds.

More than 300 novel anti-tubercular agents were identified and characterised from biological sources between 2003 and 2005 ([@bib0165]), while there were a further 450 novel entities identified from 2006 to 2009 ([@bib0680]). Furthermore, there have been 28 novel compounds isolated from microbial sources between 2008 and 2012, as listed in [Table 3](#tbl0015){ref-type="table"} . Of these, 11 were polyketides or polyketide-derived, and 10 were small peptides, further highlighting the significance of these classes of natural products.Table 3Novel microbial antitubercular compounds from 2008--2012.CompoundClassMicrobial producerActive againstMICRefs.PhomoenamideAmide*Phomopsis* sp. PSU-D15*M. tuberculosis* H37Ra6.25 μg/ml([@bib0660])Bisdethiobis(methylsulfanyl) apoaranotinPeptide*Aspergillus terreus* BCC 4651*M. tuberculosis* H37Ra25 μg/ml([@bib0360])CalpinactamPeptide*Mortierella alpine* FKI-4905*M. tuberculosis* H37Rv12.5 μg/ml([@bib0430])CordycommuninPeptide*Ophiocordyceps communis* BCC 16475*M. tuberculosis* H37Ra15 μM([@bib0355])NocardithiocinPeptide*Nocardia pseudobrasiliensis* IFM 0757*M. tuberculosis* H37Rv0.025 μg/ml([@bib0530])Sansanmycin APeptide*Streptomyces* sp. SS*M. tuberculosis* H37Rv16 μg/ml([@bib0865])Sansanmycin FPeptide*Streptomyces* sp. SS*M. tuberculosis* H37Rv16 μg/ml([@bib0865])Sansanmycin GPeptide*Streptomyces* sp. SS*M. tuberculosis* H37Rv16 μg/ml([@bib0865])Trichoderin APeptide*Trichoderma* sp. 05F148*M. tuberculosis* H37Rv0.12 μg/ml([@bib0595])Trichoderin A1Peptide*Trichoderma* sp. 05F148*M. tuberculosis* H37Rv2.0 μg/ml([@bib0595])Trichoderin BPeptide*Trichoderma* sp. 05F148*M. tuberculosis* H37Rv0.13 μg/ml([@bib0595])(3S,4R)-4,8-Dihydroxy-3-methoxy-3,4-dihydronaphthalen-1(2H)-onePolyketide*Phaeosphaeria* sp. BCC 8292*M. tuberculosis* H37Ra12.5 μg/ml([@bib0590])(4S)-3,4,8-Trihydroxy-6-methoxy-3,4-dihydronaphthalen-1(2H)-onePolyketide*Phaeosphaeria* sp. BCC 8292*M. tuberculosis* H37Ra25 μg/ml([@bib0590])(S)-4,6,8-Trihydroxy-3,4-dihydronaphthalen-1(2H)-onePolyketide*Phaeosphaeria* sp. BCC 8292*M. tuberculosis* H37Ra12.5 μg/ml([@bib0590])1-(1-Hydroxy-3,6-dimethoxy-5,8-dioxo-5,8-dihydronaphthalen-2-yl)ethyl acetatePolyketide*Phaeosphaeria* sp. BCC 8292*M. tuberculosis* H37Ra0.39 μg/ml([@bib0590])2,5,7-Trihydroxy-3-(1-(1-hydroxy-3,6-dimethoxy-5,8-dioxo-5,8-dihydronaphthalen-2-yl)ethyl)naphthalene-1,4-dionePolyketide*Phaeosphaeria* sp. BCC 8292*M. tuberculosis* H37Ra6.25 μg/ml([@bib0590])6-Ethyl-5-hydroxy-2,7-dimethoxynaphthalene-1,4-dionePolyketide*Phaeosphaeria* sp. BCC 8292*M. tuberculosis* H37Ra12.5 μg/ml([@bib0590])Biscogniazaphilone APolyketide*Biscogniauxia formosanaM. tuberculosis* H37Rv5.12 μg/ml([@bib0150])Biscogniazaphilone BPolyketide*Biscogniauxia formosanaM. tuberculosis* H37Rv2.52 μg/ml([@bib0150])Chaetoviridine EPolyketide*Chaetomium cochloides* VTh01*M. tuberculosis* H37Ra50 μg/ml([@bib0585])Mollicellin KPolyketide*Chaetomium brasilienseM. tuberculosis* H37Rv12.5 μg/ml([@bib0405])Ramariolide APolyketide*Ramaria cystidiophora* W179*M. tuberculosis* H37Rv64 μg/ml([@bib0130])3-*epi*-astrahygrolTerpene*Astraeus pteridisM. tuberculosis* H37Rv34 μg/ml([@bib0735])3-*epi*-astrapteridiolTerpene*Astraeus pteridisM. tuberculosis* H37Rv58 μg/ml([@bib0735])Astraodoric acid ATerpene*Astraeus odoratusM. tuberculosis* H37Ra50 μg/ml([@bib0040])Astraodoric acid BTerpene*Astraeus odoratusM. tuberculosis* H37Ra25 μg/ml([@bib0040])Hopane-6b,11a,22,27-tetraolTerpene*Conoideocrella tenuis* BCC 18627*M. tuberculosis* H37Ra52 μM([@bib0390])RamiferinTerpene*Kionochaeta ramiferaM. tuberculosis* H37Ra12.7 μM([@bib0115])

Natural product drug discovery works on the basis that biological diversity is the key to chemical diversity ([@bib0725]). One prerequisite for the discovery of novel bioactive compounds is choosing suitable source material which significantly increases the chance of "hitting a target". Plants have long been viewed as a common source of remedies, either in the form of traditional preparations or as pure active principles. This forms a strong basis to utilise local plants that have been traditionally used as medicine and investigate them for their active chemical constituents. In fact, Norman R. Farnsworth, one of the pioneers in the field of pharmacognosy (study of traditional medicines), highlighted that in 1985, there were 119 compounds isolated from 90 plants which were utilised as single entity medicinal agents ([@bib0260]). Most importantly, 77% of these compounds were obtained as a result of examining the plant based on an ethnomedical use, and were utilised in a manner similar to their traditional use. This emphasises the rationale of investigating traditional medicinal plants for chemical discovery.

Additionally, to further increase chemical diversity, and based on the premise that each plant hosts a number of endophytic microorganisms, it has been beneficial exploring these microbes to discover novel compounds. An example is provided by a group of microbiologists in Thailand, who investigated fungal endophytes from their local medicinal plants for bioactivity ([@bib0850]). It was shown that from 360 morphologically distinct endophytic fungi, extracts from 92 isolates were found to inhibit the growth of *M. tuberculosis* H~37~Ra (MIC of 0.0625--200 μg/ml), 6 inhibited *Plasmodium falciparum* (IC~50~ of 1.2--9.1 μg/ml), 40 showed antiviral activity against Herpes simplex virus type I (IC~50~ of 0.28--50 μg/ml), 60 exhibited anti-proliferative activity against a human oral epidermoid carcinoma cell line (EC~50~ of 0.42--20 μg/ml), and 48 extracts had anti-cancer activity against breast cancer cells (EC~50~ of 0.18--20 μg/ml). These examples highlight the mutual relationship between biological diversity and drug discovery.

Endophytes are a potential source of novel bioactive compounds. Nonetheless, fine screening, purification, and identification methods are required to target active compounds since each microorganism may contain a large pool of compounds with only few being bioactive. An example is the culturable endophytes from traditional Chinese medicinal plants ([@bib0520]). Bacterial and fungal endophytes from eight plants, traditionally used for anticancer therapy, were screened genetically for the presence of PKS and NRPS systems. Assays investigating antibacterial, antifungal, and cytotoxicity traits were also performed using crude extracts from these endophytes. The eight plants hosted 74 bacterial endophytes belonging to 14 genera, as well as 36 fungal endophytes from 10 genera. Moreover, 12% of bacterial endophytes and 58% of fungal endophytes possessed PKS machinery, while 13% of bacterial endophytes and 17% of fungal endophtyes had at least NRPS gene cluster. All of the endophytes equipped with either PKS and/or NRPS system exhibited anti-proliferative effects in at least one bioassay. From this example, it was shown that traditional medicinal plants harbour endophytes producing bioactive natural products. There was also a strong correlation between PKS/NRPS genes and bioactivity. Thus, combining genetic- and bioactivity-based de-replication steps, a streamlined method for bioactive natural product discovery was developed.

8. Indonesian traditional medicine for the treatment of tuberculosis {#sec0040}
====================================================================

Indonesia has one of the world\'s largest floral diversities. This is largely due to its complex geological history, the existence of a large number of islands with endemic species, and the tropical climate that supports the growth of a diverse range of plants. Indonesia contains two of the world\'s 25 biodiversity hotspots, the Sundaland and Wallacea regions, and has more than 40,000 different plant species, 16,500 of which are endemic ([@bib0540]). Of these plant species, approximately 10% are believed to possess some medicinal characteristics ([@bib0700]), many of which have not been investigated. Indonesian traditional herbal medicine, collectively referred to as *jamu*, has achieved a worldwide reputation for their use in treating various diseases. Approximately three-quarters of the country\'s population consume various types of *jamu* on a regular basis for healthcare ([@bib0740]). As with all traditional medicines, the development of *jamu* started by random experiments to discover the beneficial properties of plants ([@bib0745]). The traditional healers, who possessed advanced knowledge of these plants, have occupied a privileged position in society ([@bib0700]). The knowledge has mainly passed verbally from generation to generation ([@bib0455]).

Ethnobotanical drug discovery efforts resulted the discovery of the polyphenols from two frequently used traditional Indonesian medicinal plants ([@bib0740]). *Guazuma ulmifolia* Lam. (local name: daun jati belanda) was traditionally used to treat liver disease, while *Sauropus androgynus* Merr. (local name: daun katuk) reduces fever. Researchers believed that the beneficial effects of these plants were associated with the antioxidative activity of polyphenols. Subsequent phytochemical investigations isolated kaempferol from *S. androgynus* and luteolin from *G. ulmifolia*. The antioxidative properties of these compounds were confirmed by *in vitro* tests using rat hepatoma cells.

As with other cultures around the world, a number of plants have been utilised by Indonesian traditional herbalists to treat what commonly know as TB ([Table 4](#tbl0020){ref-type="table"} ). It is worth noting that as knowledge of the disease was limited, the plants used in traditional therapies for what we now know as TB were based on the symptoms the patients exhibited, such as coughing with blood-tinged sputum or shortness of breath. While a small proportion of Indonesian medicinal plants have been extensively studied and contain specific anti-tubercular compounds, most of these plants remain under-studied and may be host to many endophytes and their antibiotics compounds.Table 4Indonesian plants that were traditionally used to treat symptoms of tuberculosis.PlantLocal nameParts usedMedicine preparation*Andrographis paniculata*SambilotoLeavesGround with mortar and pestle, served with honey ([@bib0170])*Brucea javanica*Buah MakasarFruitGround with mortar and pestle ([@bib0175])*Caesalpinia sappan*SecangStemBoiled water extract of chopped pieces ([@bib0195])*Centella asiatica*PegaganAll aerial partsBoiled water extract of ground plant ([@bib0175])*Hibiscus tiliaceus*WaruLeavesBoiled water extract ([@bib0175])*Lantana camara*TembelekanLeaves and flowersBoiled water extract ([@bib0215])*Morinda citrifolia*MengkuduAll aerial partsBoiled water extract ([@bib0185])*Nasturtium indicum*Sawi TanahAll aerial partsBoiled water extract ([@bib0195])*Pluchea indica*BeluntasLeaves and rootsBoiled water extract ([@bib0170])*Rhoeo spathacea*Nanas KerangLeavesBoiled water extract ([@bib0180])*Ricinus communis*JarakLeaves and rootsBoiled water extract ([@bib0190])*Vitex trifolia*LegundiLeavesBoiled water extract ([@bib0190])

9. Concluding remarks {#sec0045}
=====================

There is a persistent battle between pathogens and drugs and thus, a constant urgency to discover novel antibiotics against these microorganisms, particularly the rapidly developing drug resistant strains of *M. tuberculosis*. The critical first step in discovering novel bioactive compounds is pin-pointing the most suitable source material. According to Professor Gary Strobel, one of the pioneers of endophyte studies, there are three important criteria for bioprospecting: significant biodiversity, a history of long-term human habitation, and the presence of native healers with a knowledge of local medicinal plants ([@bib0315]).

Home to some of the largest tropical rainforests in the world, Indonesia offers an incredible range of biodiversity, most of which has never been investigated. Biological diversity often translates into molecular diversity, increasing the possibility of isolating new chemical entities. Utilising traditional knowledge by studying plants that have been used to treat symptoms of respiratory disease may assist in narrowing down the plants as targets for investigating the production of novel antimycobacterial compounds. Furthermore, based on the premise that many plant bioactive compounds are actually produced by their microbial symbionts, exploring the endophytes from these medicinal plants will assist in isolating and producing their active components.

The ultimate aim of bioprospecting for novel compounds is to isolate compounds which are safe and efficacious for human use. Efficient screening mechanisms are crucial for targeting potential bioactive compounds. Prior knowledge of biosynthesis of polyketides and small non-ribosomal peptides greatly assists in de-replicating the plethora of compounds produced by a single microorganism. Structure elucidation of the isolated chemicals and characterisation of their biosynthetic pathways provides a basis for these novel compounds to be investigated in clinical trials and for commercial purposes. The potential of antimycobacterial drug discovery from endophytes from traditional medicinal plants is immense.
